nafamostat has been researched along with Cancer of Liver in 6 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether the administration of nafamostat mesilate (NM) reduces the risk of posthepatectomy liver failure (PHLF) in patients undergoing hepatectomy for hepatocellular carcinoma (HCC)." | 8.12 | Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure. ( Cho, JY; Han, HS; Jo, Y; Kim, M; Lee, B; Lee, HW; Lee, JS; Yoon, YS, 2022) |
| "Nafamostat mesilate is an anti-inflammatory drug that is usually used to treat pancreatitis." | 5.43 | Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. ( Chen, G; Chen, LZ; Ju, HQ; Kang, TB; Lu, YX; Mo, HY; Pan, ZZ; Sheng, H; Wang, F; Wu, QN; Xie, D; Xu, RH; Yun, JP; Zeng, ZL, 2016) |
| "To investigate whether the administration of nafamostat mesilate (NM) reduces the risk of posthepatectomy liver failure (PHLF) in patients undergoing hepatectomy for hepatocellular carcinoma (HCC)." | 4.12 | Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure. ( Cho, JY; Han, HS; Jo, Y; Kim, M; Lee, B; Lee, HW; Lee, JS; Yoon, YS, 2022) |
| "The effect of nafamostat mesilate on coagulation and fibrinolysis was investigated in a study of 22 patients with hepatocellular carcinoma who underwent a hepatic resection." | 3.69 | Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection. ( Kamakura, T; Matsumata, T; Shimada, M; Shirabe, K; Sugimachi, K; Taketomi, A, 1994) |
| " Nafamostat mesilate (FUT-175), a synthetic serine protease inhibitor, inhibited liver metastasis in a CDF1 mice model with colon 26 adenocarcinoma cells." | 3.68 | Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells. ( Fuchimoto, S; Hizuta, A; Iwagaki, H; Kimura, T; Orita, K, 1992) |
| "Nafamostat mesilate is an anti-inflammatory drug that is usually used to treat pancreatitis." | 1.43 | Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. ( Chen, G; Chen, LZ; Ju, HQ; Kang, TB; Lu, YX; Mo, HY; Pan, ZZ; Sheng, H; Wang, F; Wu, QN; Xie, D; Xu, RH; Yun, JP; Zeng, ZL, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, B | 1 |
| Cho, JY | 1 |
| Han, HS | 1 |
| Yoon, YS | 1 |
| Lee, HW | 1 |
| Lee, JS | 1 |
| Kim, M | 1 |
| Jo, Y | 1 |
| Saito, N | 1 |
| Uwagawa, T | 1 |
| Hamura, R | 1 |
| Takada, N | 1 |
| Sugano, H | 1 |
| Shirai, Y | 1 |
| Shiba, H | 1 |
| Ohashi, T | 1 |
| Yanaga, K | 1 |
| Lu, YX | 1 |
| Ju, HQ | 1 |
| Wang, F | 1 |
| Chen, LZ | 1 |
| Wu, QN | 1 |
| Sheng, H | 1 |
| Mo, HY | 1 |
| Pan, ZZ | 1 |
| Xie, D | 1 |
| Kang, TB | 1 |
| Chen, G | 1 |
| Yun, JP | 1 |
| Zeng, ZL | 1 |
| Xu, RH | 1 |
| Shimada, M | 1 |
| Matsumata, T | 1 |
| Shirabe, K | 1 |
| Kamakura, T | 1 |
| Taketomi, A | 1 |
| Sugimachi, K | 1 |
| Suzuki, H | 1 |
| Nimura, Y | 1 |
| Kamiya, J | 1 |
| Kondo, S | 1 |
| Nagino, M | 1 |
| Kanai, M | 1 |
| Miyachi, M | 1 |
| Kimura, T | 1 |
| Fuchimoto, S | 1 |
| Iwagaki, H | 1 |
| Hizuta, A | 1 |
| Orita, K | 1 |
1 review available for nafamostat and Cancer of Liver
| Article | Year |
|---|---|
Preoperative transcatheter arterial embolization for giant cavernous hemangioma of the liver with consumption coagulopathy.
Topics: Adult; Anticoagulants; Benzamidines; Combined Modality Therapy; Disseminated Intravascular Coagulati | 1997 |
5 other studies available for nafamostat and Cancer of Liver
| Article | Year |
|---|---|
Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Benzamidines; Bilirubin; Carcinoma, Hepatocellula | 2022 |
Prevention of early liver metastasis after pancreatectomy by perioperative administration of a nuclear factor-κB inhibitor in mice.
Topics: Animals; Benzamidines; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; | 2019 |
Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamidines; Cell Movement; Cel | 2016 |
Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.
Topics: Aged; Antifibrinolytic Agents; Benzamidines; Blood Coagulation; Blood Loss, Surgical; Carcinoma, Hep | 1994 |
Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antithrombins; Benzamidines; Colonic Neoplasms; Extr | 1992 |